Close Menu

NEW YORK – Responding to an ongoing need for biomarkers that can quickly and accurately predict and diagnose sepsis, Stanford University spinout Inflammatix is moving closer to commercialization with an immune response testing platform that uses machine learning to analyze isothermal mRNA expression.

Inflammatix Cofounder and CEO Tim Sweeney announced last week that the firm expects to start a clinical trial in January to support a submission to the US Food and Drug Administration for regulatory clearance.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

This webinar will provide an overview of how a pathology laboratory validated a 77-gene next-generation sequencing-based liquid biopsy assay.


This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.